Project Grant K01DA064431
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a K23 Career Development Grant of $196,020 to the University of Pennsylvania, effective September 1, 2025, through August 31, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). This award supports Dr. Eleanor Turi's mentored research training to develop expertise in ethical research methodologies with people who inject drugs (PWID), mixed methods analysis, coincidence analysis, hybrid...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $197,640 Project Grant to Massachusetts General Hospital (MGH), effective March 1, 2026 through February 28, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). This four-year research initiative will deliver clinical outcomes research and health economic analysis focused on integrating infectious disease (ID) care into rapid-access substance use disorder (SUD) bridge clinics. The project...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded a $193,751 Career Development Project Grant (CFDA 93.279: Drug Use and Addiction Research Programs) to the Trustees of Boston University, effective May 1, 2026 through April 30, 2031, to support research advancing the quality of care for Medicaid enrollees in outpatient substance use disorder (SUD) treatment facilities. The award funds the development of an independent researcher in SUD services through a rigorous...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded $399,600 through its Drug Use and Addiction Research Programs (CFDA 93.279) to support a Mentored Research Scientist Development Award (K01) focused on developing dynamic treatment regimes for personalized opioid use disorder care. Awarded on August 15, 2025, with a completion date of July 31, 2030, this five-year career development and research initiative is led by Dr. Jason Brian Gibbons at the University of Colorado...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Medical University of South Carolina a Project Grant of $210,168 under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period May 1, 2026, through April 30, 2028. This award supports basic neuroscience research investigating glutamatergic neural circuit mechanisms underlying opioid use disorder (OUD) and reward-seeking behavior. The funded research dissects pathway-specific glutamatergic...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $438,950 under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Board of Regents of the University of Nebraska, operating through the University of Nebraska Medical Center (UNMC) in Omaha. The award, made on May 1, 2026, supports an R21 exploratory/developmental research grant with a project completion date of April 30, 2028. The research investigates the mechanisms underlying polysubstance use (PSU)...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded the University of Miami a Project Grant totaling $109,652.00 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct implementation research on telehealth service delivery models for individuals who inject drugs. The research addresses the HIV and Substance Use Disorder (SUD) syndemic, which has impeded progress toward the Ending the HIV Epidemic (EHE) Initiative's goals of reducing new HIV infections by...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Rhode Island Research Office a $296,112 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct mixed-methods research examining clinician stigma as a barrier to buprenorphine treatment for opioid use disorder (OUD) among veterans. The study, titled "Bridging the Gap: Understanding Clinician Stigma in Buprenorphine Prescribing and Its Influence on Treatment...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded University of Miami $677,250 under the Drug Use and Addiction Research Programs (CFDA 93.279) on June 15, 2025, for development and testing of the Healthcare Empowerment and Advocacy for Recovery from Trafficking (HEART) intervention. The project, extending through May 31, 2028, addresses the intersecting public health emergencies of sex trafficking, opioid use disorder, and HIV epidemic by creating a peer-delivered brief...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a K01 Mentored Research Scientist Development Award of $185,571.00 to the University of Pittsburgh under the Drug Use and Addiction Research Programs (CFDA 93.279) on February 15, 2026, with completion scheduled for January 31, 2031. This career development award supports Dr. J. Travis Donahoe, a health economist and assistant professor at the University of Pittsburgh School of Public Health, in advancing as an...
The National Institute on Drug Abuse (NIDA) awarded The Miriam Hospital a $186,895 K01 Career Development Award under the Drug Use and Addiction Research Programs (CFDA 93.279) effective May 1, 2026 through April 30, 2031. This award supports research identifying optimal treatment approaches for HIV prevention and substance use treatment in people with drug use-associated wounds. The project addresses critical gaps in care delivery by evaluating wound care, pre-exposure prophylaxis (PrEP), and medications for opioid use disorder (MOUD) outcomes within the context of an evolving drug supply, including complications from additives such as xylazine. The research will employ a mixed-methods approach combining qualitative exploration of interpersonal interactions during wound care with quantitative analysis of individual and interpersonal factors influencing care preferences, leveraging an existing cohort study of people who use drugs. The award simultaneously provides career development training to the Principal Investigator to advance her research expertise at the intersection of substance use and infectious diseases. The project's central hypothesis posits that wound care delivered through mobile clinics—rather than traditional clinical settings—improves patient-provider relationships and logistical access, thereby enhancing uptake of prevention and treatment services among vulnerable populations. This research directly supports NIDA's priorities in implementation science and evidence-based treatment expansion for underserved populations affected by substance use and related infectious disease complications.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 5/13/26 | ||
| Not listed | $186.9k | 5/5/26 |